In addition to renal cell carcinoma, CD36 expression is also upregulated in many malignancies, including prostate cancer, and in patients undergoing nephrectomy, progression-free survival (PFS) is significantly reduced in patients with high CD36 expression, which is dependent on exogenous intake of cholesterol. This evidence concerns the gene CD36 and renal cell carcinoma.